JOP20190022B1 - ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري - Google Patents
ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوريInfo
- Publication number
- JOP20190022B1 JOP20190022B1 JOP/2019/0022A JOP20190022A JOP20190022B1 JO P20190022 B1 JOP20190022 B1 JO P20190022B1 JO P20190022 A JOP20190022 A JO P20190022A JO P20190022 B1 JOP20190022 B1 JO P20190022B1
- Authority
- JO
- Jordan
- Prior art keywords
- disubstituted
- crystalline
- pyrazolyl steroid
- steroid
- pyrazolyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378582P | 2016-08-23 | 2016-08-23 | |
| PCT/US2017/048267 WO2018039378A1 (en) | 2016-08-23 | 2017-08-23 | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JOP20190022A1 JOP20190022A1 (ar) | 2019-02-18 |
| JOP20190022B1 true JOP20190022B1 (ar) | 2023-03-28 |
Family
ID=59772778
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2019/0022A JOP20190022B1 (ar) | 2016-08-23 | 2017-08-23 | ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري |
| JOJO/P/2022/0305A JOP20220305A1 (ar) | 2016-08-23 | 2018-03-01 | ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري |
| JOJO/P/2022/0304A JOP20220304A1 (ar) | 2016-08-23 | 2022-11-10 | ستيرويد 19- نور 3، c3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2022/0305A JOP20220305A1 (ar) | 2016-08-23 | 2018-03-01 | ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري |
| JOJO/P/2022/0304A JOP20220304A1 (ar) | 2016-08-23 | 2022-11-10 | ستيرويد 19- نور 3، c3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US11236121B2 (https=) |
| EP (2) | EP3981763A1 (https=) |
| JP (3) | JP2019524853A (https=) |
| KR (2) | KR20230079470A (https=) |
| CN (4) | CN115974956A (https=) |
| AR (3) | AR109393A1 (https=) |
| AU (2) | AU2017315682B2 (https=) |
| BR (1) | BR112019003637A2 (https=) |
| CA (1) | CA3034262A1 (https=) |
| CL (2) | CL2019000477A1 (https=) |
| CO (1) | CO2019002596A2 (https=) |
| EA (1) | EA201990565A1 (https=) |
| EC (1) | ECSP19020141A (https=) |
| IL (2) | IL315950B1 (https=) |
| JO (3) | JOP20190022B1 (https=) |
| MA (1) | MA46042A (https=) |
| MX (2) | MX393240B (https=) |
| MY (1) | MY200479A (https=) |
| PE (2) | PE20190915A1 (https=) |
| PH (1) | PH12019500375A1 (https=) |
| SG (1) | SG11201901445TA (https=) |
| TW (3) | TWI904593B (https=) |
| WO (1) | WO2018039378A1 (https=) |
| ZA (1) | ZA201901051B (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119192266A (zh) | 2011-10-14 | 2024-12-27 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
| MX2015002252A (es) | 2012-08-21 | 2015-07-21 | Sage Therapeutics Inc | Metodos para tratar epilepsia o estado de epilepsia. |
| JP6470258B2 (ja) | 2013-04-17 | 2019-02-13 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| ES2807264T3 (es) | 2013-04-17 | 2021-02-22 | Sage Therapeutics Inc | Esteroides neuroactivos 19-nor para métodos de tratamiento |
| WO2015010054A2 (en) | 2013-07-19 | 2015-01-22 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| ES2848823T3 (es) | 2013-08-23 | 2021-08-12 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| US10577390B2 (en) | 2014-10-16 | 2020-03-03 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| ME03809B (me) | 2014-10-16 | 2021-04-20 | Sage Therapeutics Inc | KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2016123056A1 (en) | 2015-01-26 | 2016-08-04 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP4155314A1 (en) | 2015-02-20 | 2023-03-29 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| MA45599A (fr) | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| US20190233465A1 (en) | 2016-07-11 | 2019-08-01 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| TWI904593B (zh) | 2016-08-23 | 2025-11-11 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| EP3678670A1 (en) * | 2017-09-07 | 2020-07-15 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| WO2019055764A1 (en) * | 2017-09-14 | 2019-03-21 | Sage Therapeutics, Inc. | C21-N-PYRAZOLYL C3,3-DISUBSTITUTED STEROID 19 NOR, AND METHODS OF USING THE SAME |
| EP3720867A1 (en) | 2017-12-08 | 2020-10-14 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| CA3103421A1 (en) * | 2018-06-12 | 2019-12-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| IL283629B2 (en) | 2018-12-05 | 2026-03-01 | Sage Therapeutics Inc | Neuroactive steroids and methods of using them |
| CN111454318A (zh) * | 2019-01-20 | 2020-07-28 | 浙江易众化工有限公司 | 抗抑郁药物sage-217的晶型及其制备方法 |
| WO2020155057A1 (zh) * | 2019-01-31 | 2020-08-06 | 深圳仁泰医药科技有限公司 | γ-氨基丁酸调节剂的晶型X及其制备方法和应用 |
| US20220220149A1 (en) | 2019-05-28 | 2022-07-14 | Teva Czech Industries S.R.O | Solid state forms of sage-217 and processes for preparation thereof |
| CR20240234A (es) | 2019-05-31 | 2024-07-09 | Sage Therapeutics Inc | ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629) |
| CN118027131A (zh) * | 2019-08-07 | 2024-05-14 | 上海翰森生物医药科技有限公司 | 一种甾族类衍生物调节剂的盐及其晶型 |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| KR20220157426A (ko) | 2020-03-25 | 2022-11-29 | 세이지 테라퓨틱스, 인크. | 호흡기 병태의 치료를 위한 작용제의 용도 |
| US20230285417A1 (en) * | 2020-07-20 | 2023-09-14 | Sage Therapeutics, Inc. | Formulations of 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| EP4199723A4 (en) * | 2020-10-01 | 2024-09-04 | Eliem Therapeutics (UK) Ltd | METHODS OF TREATMENT OF FIBROMYALGIA WITH NEUROACTIVE STEROIDS |
| US20240122945A1 (en) | 2021-01-28 | 2024-04-18 | Sage Therapeutics, Inc. | Use of neuroactive steroids for treatment of sexual dysfunction |
| AU2022238365A1 (en) | 2021-03-17 | 2023-09-21 | Sage Therapeutics, LLC | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder |
| US20240216396A1 (en) | 2021-04-29 | 2024-07-04 | Sage Therapeutics, Inc. | Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female |
| AU2022266680A1 (en) * | 2021-04-29 | 2023-11-02 | Sage Therapeutics, LLC | 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression |
| BR112024001518A2 (pt) | 2021-07-28 | 2024-04-30 | Sage Therapeutics Inc | Formas cristalinas de um esteroide neuroativo |
| EP4479032A1 (en) | 2022-02-16 | 2024-12-25 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of cns-related disorders |
| TW202341996A (zh) | 2022-02-28 | 2023-11-01 | 美商賽吉醫療公司 | 用於治療腸胃疾病或病狀之神經活性類固醇 |
| WO2026055127A2 (en) | 2024-09-04 | 2026-03-12 | Sage Therapeutics, Inc., A Wholly Owned Subsidiary Of Supernus Pharmaceuticals, Inc. | Process for producing a gaba receptor modulator |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
| WO2001051919A2 (en) | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
| TWI305530B (en) | 2002-02-08 | 2009-01-21 | Ono Pharmaceutical Co | Piperidine derivative compound and pharmaceuticals containing same as active ingredient |
| US20110152840A1 (en) | 2009-12-23 | 2011-06-23 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| JP2014521662A (ja) | 2011-07-29 | 2014-08-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ＧＡＢＡＡ受容体のモジュレーターとしての新規な１７β−ヘテロアリール置換ステロイド |
| US10478505B2 (en) | 2011-09-23 | 2019-11-19 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| CN119192266A (zh) | 2011-10-14 | 2024-12-27 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
| SG10201606063RA (en) | 2012-01-23 | 2016-09-29 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| US20150175651A1 (en) | 2012-06-15 | 2015-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US20140050789A1 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| MX2015002252A (es) | 2012-08-21 | 2015-07-21 | Sage Therapeutics Inc | Metodos para tratar epilepsia o estado de epilepsia. |
| US9765110B2 (en) | 2012-10-08 | 2017-09-19 | Washington University | Neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| DK2925327T3 (da) | 2012-11-30 | 2024-03-25 | Univ California | Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression |
| MX365644B (es) | 2012-12-18 | 2019-06-10 | Univ Washington | Esteroides neuroactivos sustituidos con 19-alcoxi-17, profarmacos de los mismos, y metodos de tratamiento usando los mismos. |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| ES2807264T3 (es) | 2013-04-17 | 2021-02-22 | Sage Therapeutics Inc | Esteroides neuroactivos 19-nor para métodos de tratamiento |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| JP6470258B2 (ja) | 2013-04-17 | 2019-02-13 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| WO2015010054A2 (en) | 2013-07-19 | 2015-01-22 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| ES2848823T3 (es) | 2013-08-23 | 2021-08-12 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
| HRP20201126T1 (hr) | 2014-05-29 | 2020-12-11 | Sage Therapeutics, Inc. | Neuroaktivni steroidi, njihovi pripravci i uporabe |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| US10577390B2 (en) | 2014-10-16 | 2020-03-03 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| ME03809B (me) * | 2014-10-16 | 2021-04-20 | Sage Therapeutics Inc | KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2016123056A1 (en) | 2015-01-26 | 2016-08-04 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP4155314A1 (en) | 2015-02-20 | 2023-03-29 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US20180311258A1 (en) | 2015-04-10 | 2018-11-01 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| AR105044A1 (es) | 2015-06-18 | 2017-08-30 | Sage Therapeutics Inc | Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente |
| UY36741A (es) | 2015-06-21 | 2016-12-30 | Prevacus Inc | Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales |
| US20180250313A1 (en) | 2015-09-08 | 2018-09-06 | Viewpoint Therapeutics, Inc. | Compounds and formulations for treating ophthalmic diseases |
| EA036155B1 (ru) | 2015-10-16 | 2020-10-06 | Маринус Фармасьютикалс, Инк. | Инъекционные составы нейростероида, содержащие наночастицы |
| EP3377070A4 (en) | 2015-11-20 | 2019-07-10 | Sage Therapeutics, Inc. | COMPOUNDS AND METHOD FOR THEIR USE |
| HK1258616A1 (zh) | 2016-03-08 | 2019-11-15 | Sage Therapeutics, Inc. | 神经活性类固醇、组合物、及其用途 |
| US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
| MA45599A (fr) | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| US20190233465A1 (en) | 2016-07-11 | 2019-08-01 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| TWI904593B (zh) | 2016-08-23 | 2025-11-11 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| CN108727453A (zh) | 2017-04-20 | 2018-11-02 | 华东理工大学 | 新型pd-1抑制剂及其应用 |
| WO2019018119A1 (en) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI |
| WO2019045121A1 (en) | 2017-08-31 | 2019-03-07 | Takeda Pharmaceutical Company Limited | TREATMENT OF CNS DISEASES |
| EP3678670A1 (en) | 2017-09-07 | 2020-07-15 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| WO2019051477A1 (en) | 2017-09-11 | 2019-03-14 | Sage Therapeutics, Inc. | METHODS OF TREATING EPILEPSY OR EPILEPTIC MALE CONDITION |
| WO2019055764A1 (en) | 2017-09-14 | 2019-03-21 | Sage Therapeutics, Inc. | C21-N-PYRAZOLYL C3,3-DISUBSTITUTED STEROID 19 NOR, AND METHODS OF USING THE SAME |
| AU2018364659A1 (en) | 2017-11-10 | 2020-05-28 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating genetic epileptic disoders |
| EP3720867A1 (en) | 2017-12-08 | 2020-10-14 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| EP3728284B1 (en) | 2017-12-22 | 2024-08-21 | Sage Therapeutics, Inc. | 19-homo, 3.alpha.-hydroxy-steroid-20-one compounds for treating cns disorders |
| CN111741965B (zh) | 2017-12-22 | 2024-06-25 | 萨奇治疗股份有限公司 | 治疗中枢神经系统疾病的组合物和方法 |
| MA51568A (fr) | 2018-01-12 | 2021-04-21 | Sage Therapeutics Inc | Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central |
| CA3103421A1 (en) | 2018-06-12 | 2019-12-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| CN113166193B (zh) | 2018-10-12 | 2025-08-19 | 萨奇治疗股份有限公司 | 用于治疗cns病症的在位置10处被环状基团取代的神经活性类固醇 |
| CA3116892A1 (en) | 2018-10-19 | 2020-04-23 | Sage Therapeutics, Inc. | 9(11)-unsaturated neuroactive steroids and their methods of use |
| IL283629B2 (en) | 2018-12-05 | 2026-03-01 | Sage Therapeutics Inc | Neuroactive steroids and methods of using them |
| CN113195512A (zh) | 2018-12-21 | 2021-07-30 | 萨奇治疗股份有限公司 | 3.α.-羟基-17.β.-酰胺神经活性类固醇及其组合物 |
| TW202523658A (zh) | 2019-05-24 | 2025-06-16 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| CR20240234A (es) | 2019-05-31 | 2024-07-09 | Sage Therapeutics Inc | ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629) |
| US20230257415A1 (en) | 2019-06-27 | 2023-08-17 | Sage Therapeutics, Inc. | Compounds for treating cns disorders |
| AU2020304673A1 (en) | 2019-06-27 | 2022-01-20 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| JP7787635B2 (ja) | 2019-06-27 | 2025-12-17 | セージ セラピューティクス， エルエルシー | Ｃｎｓ障害を治療するための組成物及び方法 |
| US20230018765A1 (en) | 2019-12-05 | 2023-01-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| TW202143976A (zh) | 2020-03-18 | 2021-12-01 | 美商賽吉醫療公司 | 神經活性類固醇及其使用方法 |
| KR20220157426A (ko) | 2020-03-25 | 2022-11-29 | 세이지 테라퓨틱스, 인크. | 호흡기 병태의 치료를 위한 작용제의 용도 |
| IL299176A (en) | 2020-06-24 | 2023-02-01 | Sage Therapeutics Inc | 3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl substituted neuroactive steroids and compositions thereof |
| US20230285417A1 (en) | 2020-07-20 | 2023-09-14 | Sage Therapeutics, Inc. | Formulations of 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| WO2022115381A1 (en) | 2020-11-25 | 2022-06-02 | Sage Therapeutics, Onc. | Compositions and methods for treating cns disorders cross reference to related application |
| US20240122945A1 (en) | 2021-01-28 | 2024-04-18 | Sage Therapeutics, Inc. | Use of neuroactive steroids for treatment of sexual dysfunction |
| WO2022177718A1 (en) | 2021-02-18 | 2022-08-25 | Sage Therapeutics, Inc. | Use of neuroactive steroid for treatment of sexual dysfunction |
| AU2022238365A1 (en) | 2021-03-17 | 2023-09-21 | Sage Therapeutics, LLC | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder |
| CN117897160A (zh) | 2021-04-12 | 2024-04-16 | 萨奇治疗股份有限公司 | 特发性震颤的治疗 |
| US20240216396A1 (en) | 2021-04-29 | 2024-07-04 | Sage Therapeutics, Inc. | Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female |
| AU2022266680A1 (en) | 2021-04-29 | 2023-11-02 | Sage Therapeutics, LLC | 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression |
| EP4479032A1 (en) | 2022-02-16 | 2024-12-25 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of cns-related disorders |
| TW202341996A (zh) | 2022-02-28 | 2023-11-01 | 美商賽吉醫療公司 | 用於治療腸胃疾病或病狀之神經活性類固醇 |
-
2017
- 2017-08-23 TW TW113108231A patent/TWI904593B/zh active
- 2017-08-23 WO PCT/US2017/048267 patent/WO2018039378A1/en not_active Ceased
- 2017-08-23 CA CA3034262A patent/CA3034262A1/en active Pending
- 2017-08-23 JP JP2019510657A patent/JP2019524853A/ja not_active Withdrawn
- 2017-08-23 PE PE2019000416A patent/PE20190915A1/es unknown
- 2017-08-23 BR BR112019003637A patent/BR112019003637A2/pt not_active Application Discontinuation
- 2017-08-23 AU AU2017315682A patent/AU2017315682B2/en active Active
- 2017-08-23 MA MA046042A patent/MA46042A/fr unknown
- 2017-08-23 TW TW112101437A patent/TWI854445B/zh active
- 2017-08-23 TW TW106128611A patent/TWI808945B/zh active
- 2017-08-23 KR KR1020237017309A patent/KR20230079470A/ko active Pending
- 2017-08-23 IL IL315950A patent/IL315950B1/en unknown
- 2017-08-23 EP EP21190443.8A patent/EP3981763A1/en active Pending
- 2017-08-23 CN CN202210890054.4A patent/CN115974956A/zh active Pending
- 2017-08-23 IL IL302480A patent/IL302480A/en unknown
- 2017-08-23 CN CN202210890024.3A patent/CN115974954A/zh active Pending
- 2017-08-23 AR ARP170102330A patent/AR109393A1/es not_active Application Discontinuation
- 2017-08-23 MX MX2019002193A patent/MX393240B/es unknown
- 2017-08-23 EA EA201990565A patent/EA201990565A1/ru unknown
- 2017-08-23 CN CN202210890025.8A patent/CN115974955A/zh active Pending
- 2017-08-23 PE PE2024000634A patent/PE20241580A1/es unknown
- 2017-08-23 US US16/326,977 patent/US11236121B2/en active Active
- 2017-08-23 SG SG11201901445TA patent/SG11201901445TA/en unknown
- 2017-08-23 CN CN201780063826.4A patent/CN110088091A/zh active Pending
- 2017-08-23 JO JOP/2019/0022A patent/JOP20190022B1/ar active
- 2017-08-23 EP EP17761714.9A patent/EP3504189A1/en not_active Withdrawn
- 2017-08-23 MY MYPI2019000844A patent/MY200479A/en unknown
- 2017-08-23 KR KR1020197008069A patent/KR20190040043A/ko not_active Ceased
-
2018
- 2018-03-01 JO JOJO/P/2022/0305A patent/JOP20220305A1/ar unknown
-
2019
- 2019-02-19 ZA ZA2019/01051A patent/ZA201901051B/en unknown
- 2019-02-21 PH PH12019500375A patent/PH12019500375A1/en unknown
- 2019-02-22 MX MX2022007432A patent/MX2022007432A/es unknown
- 2019-02-22 CL CL2019000477A patent/CL2019000477A1/es unknown
- 2019-03-20 CO CONC2019/0002596A patent/CO2019002596A2/es unknown
- 2019-03-22 EC ECSENADI201920141A patent/ECSP19020141A/es unknown
- 2019-12-10 CL CL2019003610A patent/CL2019003610A1/es unknown
-
2021
- 2021-08-06 US US17/396,464 patent/US11884696B2/en active Active
-
2022
- 2022-02-08 AU AU2022200811A patent/AU2022200811B9/en active Active
- 2022-04-08 AR ARP220100895A patent/AR125321A2/es unknown
- 2022-04-08 AR ARP220100894A patent/AR125320A2/es unknown
- 2022-11-07 JP JP2022178009A patent/JP2023002846A/ja active Pending
- 2022-11-10 JO JOJO/P/2022/0304A patent/JOP20220304A1/ar unknown
-
2023
- 2023-08-24 US US18/455,324 patent/US12358942B2/en active Active
-
2024
- 2024-05-07 JP JP2024075299A patent/JP2024097878A/ja not_active Withdrawn
-
2025
- 2025-06-11 US US19/234,808 patent/US20250304615A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20190022B1 (ar) | ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري | |
| PH12019501842A1 (en) | Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors | |
| PH12018501096A1 (en) | Modulators of chemokine receptors | |
| MX2020001278A (es) | Sintesis de compuestos de carbamoilpiridona policiclica. | |
| AU2014375265A1 (en) | Novel pyrazolyl-heteroarylamides as pesticides | |
| EA201790884A8 (ru) | 6-алкил-7-гидрокси-4-ен-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr | |
| MX2017002214A (es) | Proceso para la preparacion de 5-fluoro-1h-pirazoles partiendo de hexafluoropropeno. | |
| EA201790879A1 (ru) | 6-альфа-алкил-3,7-дионовые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr | |
| EA033445B1 (ru) | 5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr | |
| EA201790885A1 (ru) | 6α-АЛКИЛ-6,7-ДИОНОВЫЕ СТЕРОИДЫ В КАЧЕСТВЕ ПРОМЕЖУТОЧНЫХ СОЕДИНЕНИЙ ДЛЯ ПОЛУЧЕНИЯ СТЕРОИДНЫХ МОДУЛЯТОРОВ FXR | |
| TW201613871A (en) | Process for the preparation of 5-fluoro-1H-pyrazoles starting from hexafluoropropene | |
| MX2019004024A (es) | Metodo para preparar acetofenonas sustituidas con ciclopropilo. | |
| IN2014MU01192A (https=) | ||
| MX2019003684A (es) | Formas cristalinas de un derivado de acido biliar. | |
| MX2023009431A (es) | Metodo para crear un compuesto a base de mercurio, compuesto a base de mercurio, metodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio. | |
| IN2014MU00195A (https=) | ||
| MX2017010901A (es) | Colorantes de acido trisazo. | |
| IN2014MU00194A (https=) | ||
| IN2014MU01196A (https=) | ||
| WO2015075693A8 (en) | Process for the synthesis of (11 beta,17alpha)-17-acetoxy-11 -methyl-19-norpregn-4-en-3,20-dione | |
| MX2018007638A (es) | Proceso mejorado para preparar crotonilaminopiridinas. | |
| IN2014MU00858A (https=) | ||
| IN2014MU01195A (https=) | ||
| MX2018011117A (es) | Forma cristalina. | |
| IN2013MU01524A (https=) |